Bausch + Lomb (NYSE:BLCO – Get Rating) and Warby Parker (NYSE:WRBY – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings.
Valuation and Earnings
This table compares Bausch + Lomb and Warby Parker’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bausch + Lomb||$3.77 billion||1.46||$182.00 million||N/A||N/A|
|Warby Parker||$540.80 million||2.39||-$144.27 million||N/A||N/A|
Institutional and Insider Ownership
98.6% of Warby Parker shares are held by institutional investors. 25.4% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Bausch + Lomb and Warby Parker’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Bausch + Lomb||N/A||N/A||N/A|
This is a breakdown of current recommendations for Bausch + Lomb and Warby Parker, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Bausch + Lomb||0||4||7||0||2.64|
Bausch + Lomb presently has a consensus target price of $23.33, indicating a potential upside of 48.15%. Warby Parker has a consensus target price of $32.20, indicating a potential upside of 137.29%. Given Warby Parker’s higher probable upside, analysts plainly believe Warby Parker is more favorable than Bausch + Lomb.
Bausch + Lomb Company Profile (Get Rating)
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments and treatments for various eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases; and and contact lenses for therapeutic use. The Surgical segment provides medical device equipment, consumables, and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Warby Parker Company Profile (Get Rating)
Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray. The company also offers eye exams and vision tests directly to consumers through its retail stores, website, and mobile apps. As of May 16, 2022, it had 160 retail stores in the United States and Canada. The company was formerly known as JAND, Inc. and changed its name to Warby Parker Inc. in June 2021. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.